BR112022011177A2 - Domínios de repetição de anquirina projetados com resíduos de superfície alterados - Google Patents

Domínios de repetição de anquirina projetados com resíduos de superfície alterados

Info

Publication number
BR112022011177A2
BR112022011177A2 BR112022011177A BR112022011177A BR112022011177A2 BR 112022011177 A2 BR112022011177 A2 BR 112022011177A2 BR 112022011177 A BR112022011177 A BR 112022011177A BR 112022011177 A BR112022011177 A BR 112022011177A BR 112022011177 A2 BR112022011177 A2 BR 112022011177A2
Authority
BR
Brazil
Prior art keywords
proteins
anchyrin
surface residues
altered surface
repetition
Prior art date
Application number
BR112022011177A
Other languages
English (en)
Portuguese (pt)
Inventor
Binz Kaspar
Schilling Johannes
Forrer Patrik
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of BR112022011177A2 publication Critical patent/BR112022011177A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
BR112022011177A 2019-12-11 2020-12-11 Domínios de repetição de anquirina projetados com resíduos de superfície alterados BR112022011177A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP19215434 2019-12-11
EP19215433 2019-12-11
EP19215436 2019-12-11
EP19215435 2019-12-11
EP20161059 2020-03-04
EP20181234 2020-06-19
PCT/EP2020/085855 WO2021116462A1 (en) 2019-12-11 2020-12-11 Designed ankyrin repeat domains with altered surface residues

Publications (1)

Publication Number Publication Date
BR112022011177A2 true BR112022011177A2 (pt) 2022-09-27

Family

ID=73790118

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022011177A BR112022011177A2 (pt) 2019-12-11 2020-12-11 Domínios de repetição de anquirina projetados com resíduos de superfície alterados
BR112022011456A BR112022011456A2 (pt) 2019-12-11 2020-12-11 Proteínas recombinantes de ligação a complexo de peptídeo-mhc e geração e uso das mesmas

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112022011456A BR112022011456A2 (pt) 2019-12-11 2020-12-11 Proteínas recombinantes de ligação a complexo de peptídeo-mhc e geração e uso das mesmas

Country Status (11)

Country Link
US (4) US20220106707A1 (cg-RX-API-DMAC7.html)
EP (2) EP4073091A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023506765A (cg-RX-API-DMAC7.html)
KR (2) KR20220113491A (cg-RX-API-DMAC7.html)
CN (2) CN115003689A (cg-RX-API-DMAC7.html)
AU (2) AU2020402581A1 (cg-RX-API-DMAC7.html)
BR (2) BR112022011177A2 (cg-RX-API-DMAC7.html)
CA (2) CA3161321A1 (cg-RX-API-DMAC7.html)
IL (2) IL293698A (cg-RX-API-DMAC7.html)
MX (2) MX2022007122A (cg-RX-API-DMAC7.html)
WO (2) WO2021116469A2 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020402581A1 (en) 2019-12-11 2022-06-23 Molecular Partners Ag Designed ankyrin repeat domains with altered surface residues
MX2022013945A (es) 2020-05-06 2023-02-14 Molecular Partners Ag Nuevas proteinas de union a repeticiones de anquirina y sus usos.
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
EP3957649A1 (en) * 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
US11981710B2 (en) 2020-08-18 2024-05-14 Athebio Ag N-terminal capping modules of ankyrin repeat domains
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
WO2022190016A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
EP4387984A1 (en) * 2021-08-17 2024-06-26 Athebio AG Variants of ankyrin repeat domains
WO2023021050A1 (en) * 2021-08-17 2023-02-23 Athebio Ag Variants of ankyrin repeat domains
EP4137508A1 (en) * 2021-08-17 2023-02-22 Athebio AG Variants of ankyrin repeat domains
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
CA3240046A1 (en) * 2021-12-14 2023-06-22 Cdr-Life Ag Dual mhc-targeting t cell engager
CA3262553A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag REHEARSAL AREAS DESIGNED WITH MODIFIED CHARGES AND THEIR USE
EP4587046A1 (en) 2022-09-14 2025-07-23 CDR-Life AG Mage-a4 peptide dual t cell engagers
EP4673159A1 (en) 2023-02-27 2026-01-07 Molecular Partners AG Darpins for use in reducing renal accumulation of drugs
EP4694904A2 (en) 2023-04-13 2026-02-18 REGENXBIO Inc. Targeting aav capsids, methods of manufacturing and using same
WO2024251628A1 (en) * 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd16a binding proteins and their use
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
WO2025163082A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Dll3-specific binding constructs and their use in radiotherapy
WO2025163144A1 (en) * 2024-01-31 2025-08-07 Molecular Partners Ag Recombinant mesothelin binding proteins and their use
DE202024101891U1 (de) 2024-04-16 2025-07-18 Igus Gmbh Leitungsführungsvorrichtung für Reinraumanwendungen sowie Halteelement dafür
WO2025250756A2 (en) * 2024-05-30 2025-12-04 Aethon Therapeutics, Inc. Compositions and methods for binding to covalent peptide conjugates containing divarasib
WO2026093563A2 (en) 2024-10-31 2026-05-07 Molecular Partners Ag Multispecific binding proteins and their use
WO2026150109A1 (en) 2025-01-10 2026-07-16 Molecular Partners Ag Mesothelin-specific binding constructs and their use in radiotherapy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
KR20070085314A (ko) 2004-11-12 2007-08-27 바이엘 쉐링 파마 악티엔게젤샤프트 재조합 뉴캐슬 질환 바이러스
KR101268939B1 (ko) 2005-07-08 2013-05-30 유니버시티 오브 취리히 융합 폴리펩티드의 공번역 전좌를 사용한 파아지디스플레이
HUE025636T2 (en) 2007-07-27 2016-04-28 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
NZ592591A (en) 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制vegf-a受體交互作用的經修飾結合性蛋白質
EP3514169B1 (en) 2010-11-26 2024-03-06 Molecular Partners AG Designed repeat proteins binding to serum albumin
WO2012149439A2 (en) * 2011-04-29 2012-11-01 Janssen Biotech, Inc. Il4/il13 binding repeat proteins and uses
SG11201408196RA (en) 2012-06-28 2015-03-30 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2906591A1 (en) 2012-10-15 2015-08-19 Universität Zürich Bispecific her2 ligands for cancer therapy
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
ES2740930T3 (es) 2014-03-14 2020-02-07 Immunocore Ltd Bibliotecas de TCR
US20170226158A1 (en) * 2014-08-11 2017-08-10 Medimmune Limited Intracellular antigen binding
EP3286222A4 (en) 2015-03-23 2018-08-08 The Johns Hopkins University Hla-restricted epitopes encoded by somatically mutated genes
US9458211B1 (en) 2015-04-02 2016-10-04 Molecular Partners Ag Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains
JP7599819B2 (ja) 2016-06-02 2024-12-16 イムノコア リミテッド gp100特異的TCR-抗CD3 scFv融合タンパク質の投薬レジメン
MY196882A (en) 2016-09-22 2023-05-08 Molecular Partners Ag Recombinant binding proteins and their use
US12065479B2 (en) * 2017-11-16 2024-08-20 The Regents Of The University Of California Force sensor cleavage domain containing chimeric polypeptides and methods of use thereof
CA3139164A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant fap binding proteins and their use
EP3980452A1 (en) 2019-06-04 2022-04-13 Molecular Partners AG Recombinant 4-1bb binding proteins and their use
JP2022535564A (ja) 2019-06-04 2022-08-09 モレキュラー パートナーズ アクチェンゲゼルシャフト 多選択性タンパク質
KR20220016944A (ko) 2019-06-04 2022-02-10 몰리큘라 파트너스 아게 개선된 안정성을 갖는 설계된 안키린 반복 도메인
CN114945584A (zh) 2019-12-11 2022-08-26 分子合作伙伴股份公司 重组肽-mhc复合物结合蛋白及其生成和用途
AU2020402581A1 (en) * 2019-12-11 2022-06-23 Molecular Partners Ag Designed ankyrin repeat domains with altered surface residues
MX2022013945A (es) * 2020-05-06 2023-02-14 Molecular Partners Ag Nuevas proteinas de union a repeticiones de anquirina y sus usos.
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
AU2021271131A1 (en) 2020-05-14 2022-12-15 Molecular Partners Ag Recombinant CD40 binding proteins and their use

Also Published As

Publication number Publication date
US20230243070A1 (en) 2023-08-03
CA3161321A1 (en) 2021-06-17
KR20220113491A (ko) 2022-08-12
EP4073091A1 (en) 2022-10-19
WO2021116462A1 (en) 2021-06-17
JP2023506757A (ja) 2023-02-20
US11578427B2 (en) 2023-02-14
US20220064234A1 (en) 2022-03-03
CN114929730A (zh) 2022-08-19
IL293698A (en) 2022-08-01
WO2021116469A3 (en) 2021-12-02
KR20220113492A (ko) 2022-08-12
AU2020402581A1 (en) 2022-06-23
JP2023506765A (ja) 2023-02-20
US12435445B2 (en) 2025-10-07
AU2020399230A1 (en) 2022-06-23
US20220106707A1 (en) 2022-04-07
CN115003689A (zh) 2022-09-02
AU2020402581A9 (en) 2022-07-14
EP4073092A2 (en) 2022-10-19
US20230340698A1 (en) 2023-10-26
BR112022011456A2 (pt) 2022-08-23
MX2022007120A (es) 2022-09-09
MX2022007122A (es) 2022-09-09
WO2021116469A2 (en) 2021-06-17
CA3161326A1 (en) 2021-06-17
JP7794740B2 (ja) 2026-01-06
IL293704A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
MX2022007122A (es) Dominios de repetición de anquirina diseñados con residuos de superficie alterados.
BR112019005587A2 (pt) proteínas de ligação recombinantes e sua utilização
BR112012027765A2 (pt) métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
BR112017016765A2 (pt) composição para tratamento de tecido compreendendo ésteres de poliol insaturados metatetizados
BR112022022456A2 (pt) Proteínas de ligação de repetição de anquirina e seus usos
EP4477662A3 (en) Nucleic acid molecules and uses thereof
BR112017019412A2 (pt) proteínas ligadoras de tslp
BR112017020986A2 (pt) proteínas de ligação recombinantes e seu uso
BR112022002831A2 (pt) Formulações anti-c5 de alta concentração
BR112018000604A2 (pt) moléculas de anticorpo que ligam cd45
MX2019012452A (es) Meganucleasas diseñadas especificas para secuencias de reconocimiento en el gen pcsk9.
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
BR112017015773A2 (pt) muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo
CO2022017445A2 (es) Proteínas multiespecíficas
MX2019003376A (es) Tratamiento de aav de la enfermedad de huntington.
BR112014032316A2 (pt) proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
BR112013017711A2 (pt) novas composições de wnt e usos terapêuticos de tais composições
MX2023007067A (es) Proteinas recombinantes de union a cd3 y su uso.
BR112018014540A2 (pt) formulações/composições compreendendo inibidor de btk
MX2021014649A (es) Dominio de repetición de anquirina diseñado con estabilidad mejorada.
MX2023007229A (es) Constructo de arn.
BR112017002166A2 (pt) terapias antibióticas de peptídeos derivados do búfalo d?água
MX2018005154A (es) Anticuerpos de dominio unico dirigidos contra el virus de la inmunodeficiencia humana.
BR112017016388A2 (pt) cenicriviroc para o tratamento da fibrose
CO2018001188A2 (es) Moléculas de fusión con especificidad de unión para pioverdina tipo i, ii y iii y pioquelina

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]